{"gene":"ADAMTS1","run_date":"2026-06-09T22:02:41","timeline":{"discoveries":[{"year":1999,"finding":"ADAMTS1/METH-1 is a secreted, proteolytically processed protein with metalloprotease, disintegrin-like, and thrombospondin-type-1 repeat domains that inhibits endothelial cell proliferation and suppresses FGF-2- and VEGF-induced angiogenesis in vivo (cornea pocket and CAM assays), establishing it as an anti-angiogenic factor.","method":"Recombinant protein production, endothelial cell proliferation assay, cornea pocket assay, chorioallantoic membrane assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vivo and in vitro assays with recombinant protein, replicated across two model systems","pmids":["10438512"],"is_preprint":false},{"year":1999,"finding":"ADAMTS1 is an active metalloprotease: it forms a covalent complex with alpha2-macroglobulin (proteinase trapping), and a point mutation in the zinc-binding motif abolishes this activity. The prodomain is removed by furin endopeptidase in the secretory pathway, as shown by impaired processing in furin-deficient LoVo cells restored by furin co-expression. The mature protein associates with the extracellular matrix.","method":"alpha2-macroglobulin trapping assay, zinc-binding domain point mutagenesis, furin-deficient cell line complementation, co-expression rescue","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic activity confirmed by proteinase trapping, active-site mutagenesis, and genetic rescue in furin-deficient cells","pmids":["10373500"],"is_preprint":false},{"year":2000,"finding":"Secreted pro-ADAMTS1 (METH-1) is processed in two consecutive steps: (1) furin cleaves the prodomain to release an 87 kDa active form (p87); (2) MMP-2, MMP-8, or MMP-15 further cleave p87 at the C-terminal end to release a 65 kDa form (p65) lacking two thrombospondin repeats. The p65 form shows reduced affinity for heparin and reduced suppression of endothelial cell proliferation compared to p87.","method":"Furin inhibitors, incubation with purified furin, MMP inhibitors, incubation with recombinant MMP-2/8/15, heparin affinity chromatography, endothelial cell proliferation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — sequential processing demonstrated with purified enzymes, specific inhibitors, and functional readout","pmids":["10944521"],"is_preprint":false},{"year":2002,"finding":"ADAMTS1 cleaves aggrecan at multiple sites including the Glu373-Ala site in the interglobular domain, classifying it as an aggrecanase. A point mutation in the zinc-binding domain abolishes catalytic activity; a furin-site mutant retains latency. ADAMTS1 is inhibited by TIMP-2 and TIMP-3 and by a specific monoclonal antibody.","method":"In vitro protease assay on ECM proteins, zinc-binding domain point mutagenesis, furin-site mutagenesis, peptide substrate activity assay, TIMP inhibition assay, monoclonal antibody neutralization","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods including mutagenesis and inhibitor validation in a single study","pmids":["12054629"],"is_preprint":false},{"year":2003,"finding":"ADAMTS1 inhibits VEGFR2 phosphorylation and endothelial cell proliferation by directly binding and sequestering VEGF165 via its C-terminal region. Binding requires the heparin-binding domain of VEGF165 (VEGF121, which lacks this domain, does not bind). The VEGF-ADAMTS1 complex is reversible, and active VEGF can be recovered. The complex was also detected in tumor extracts.","method":"Co-immunoprecipitation, chemical cross-linking, domain deletion analysis, VEGFR2 phosphorylation assay, endothelial cell proliferation assay, tumor extract co-IP","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding confirmed by co-IP and cross-linking, domain mapping, functional VEGFR2 phosphorylation readout, and in vivo tumor extract validation","pmids":["12716911"],"is_preprint":false},{"year":2003,"finding":"ADAMTS1 protein localizes to cytoplasmic secretory vesicles as a 110 kDa pro-form in mural granulosa cells, and accumulates as an 85 kDa mature form in the extracellular matrix of the cumulus-oocyte complex (COC) during matrix expansion. ADAMTS1 cleaves versican in the expanded COC matrix, generating a 70 kDa N-terminal fragment (neoepitope DPEAAE). Versican cleavage is reduced in PRKO mouse ovaries lacking ADAMTS1 induction.","method":"Peptide antibodies against pro-domain and metalloprotease domain, immunofluorescence, Western blot, neoepitope immunodetection, progesterone receptor knockout (PRKO) mouse model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — subcellular localization by immunofluorescence, substrate cleavage by neoepitope detection, genetic loss-of-function confirmation in PRKO mice","pmids":["12907688"],"is_preprint":false},{"year":2004,"finding":"ADAMTS1 gene transcription in granulosa cells is co-regulated by LH (via cAMP/PKA/CEBP-beta) and progesterone receptor (PR-A/B acting as an inducible coregulator). Three Sp1/Sp3 GC-rich binding sites, a nuclear factor 1-like site, and CEBP-beta sites in the proximal promoter are required; PR stimulates promoter activity without a consensus PR response element.","method":"Promoter-luciferase reporter assays with truncations and site-specific mutants, transfection in rat granulosa cells, PR antagonist (ZK98299), PRA/PRB co-transfection, cAMP analogs","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple promoter deletion and mutagenesis constructs with pharmacological and genetic manipulation of the pathway","pmids":["15256533"],"is_preprint":false},{"year":2005,"finding":"Fibulin-1 interacts with ADAMTS1 via the C-terminal region of ADAMTS1, as identified by yeast two-hybrid screening and confirmed by ligand affinity chromatography, co-immunoprecipitation, pulldown assays, and ELISA. Fibulin-1 acts as a cofactor, enhancing ADAMTS1-mediated cleavage of aggrecan without itself being a substrate.","method":"Yeast two-hybrid screen, ligand affinity chromatography, co-immunoprecipitation, pulldown assay, ELISA, in vitro aggrecan cleavage assay, in vivo co-localization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding confirmed by four orthogonal methods, functional enhancement of protease activity demonstrated","pmids":["16061471"],"is_preprint":false},{"year":2005,"finding":"ADAMTS1 is up-regulated in wounded skin; macrophages are the initial source, followed by keratinocytes and fibroblasts. At low concentrations, ADAMTS1 stimulates fibroblast migration via its proteolytic activity; at high concentrations it inhibits migration by binding FGF-2 and suppressing its pro-migratory activity. Similar dual effects are observed with endothelial cells.","method":"Immunofluorescence in wound tissue, ADAMTS1 knockout mouse skin phenotype, fibroblast/endothelial cell migration assays with recombinant ADAMTS1, protease-dead mutant, FGF-2 binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple cell-based assays with recombinant protein, protease-dead mutant, and KO mouse comparison, single lab","pmids":["15843381"],"is_preprint":false},{"year":2006,"finding":"ADAMTS1 cleaves tissue factor pathway inhibitor-2 (TFPI-2), removing its protease-sensitive C-terminal region and altering its extracellular localization and binding properties. The interaction was identified by yeast two-hybrid screening and confirmed by biochemical and cell-based assays.","method":"Yeast two-hybrid screen, co-immunoprecipitation, biochemical cleavage assay, cell-based localization assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — yeast two-hybrid plus biochemical confirmation but single lab, limited functional follow-up","pmids":["16641089"],"is_preprint":false},{"year":2006,"finding":"Proteomics (DIGE) identified nidogen-1, nidogen-2, desmocollin-3, dystroglycan-1, and Mac-2-binding protein as putative substrates of ADAMTS1 in conditioned medium; nidogen-1 and nidogen-2 were validated as cleavage substrates by immunochemical analysis.","method":"DIGE (2D difference gel electrophoresis), mass spectrometry, immunochemical validation, conditioned medium from ADAMTS1-overexpressing vs. parental cells","journal":"Proteomics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — proteomics discovery with immunochemical validation, single lab, limited mechanistic depth","pmids":["16511810"],"is_preprint":false},{"year":2006,"finding":"ADAMTS1 promotes tumor metastasis through its metalloproteinase activity: overexpression of full-length ADAMTS1 (but not a protease-dead mutant) promotes pulmonary metastasis and tumor angiogenesis, sheds membrane-bound HB-EGF and amphiregulin (AR), and activates EGFR and ErbB-2. Autoproteolytic N- and C-terminal fragments of ADAMTS1 each inhibit metastasis and suppress Erk1/2 activation by soluble HB-EGF and AR.","method":"Overexpression of full-length vs. protease-dead ADAMTS1 mutant (E/Q) and cleavage fragments in tumor cell lines, pulmonary metastasis assay in mice, EGFR/ErbB-2 phosphorylation assay, EGF ligand shedding assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytic mutant vs. WT comparison, multiple cell lines, in vivo metastasis model, mechanistic signaling readouts","pmids":["16314835"],"is_preprint":false},{"year":2008,"finding":"Endocardial Brg1 (a chromatin remodeling protein) represses ADAMTS1 expression in the endocardium overlying developing trabeculae. ADAMTS1, a secreted matrix metalloproteinase, degrades cardiac jelly components; its repression is required for trabecular growth. Later in embryogenesis, ADAMTS1 expression initiates in the endocardium to degrade cardiac jelly and limit excessive trabeculation.","method":"Genetic mouse models (Brg1 conditional knockout in endocardium), in vivo cardiac phenotyping, expression analysis","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO genetic epistasis with defined morphogenetic phenotype, two developmental timepoints studied","pmids":["18267097"],"is_preprint":false},{"year":2008,"finding":"ADAMTS1 cleaves the ectodomain of syndecan-4, resulting in altered cytoskeletal organization, loss of focal adhesions, and increased cell migration. ADAMTS1 proteolytic action phenocopies genetic deletion of syndecan-4 with respect to focal adhesions.","method":"Recombinant ADAMTS1 cleavage of syndecan-4, syndecan-4 null cells, immunofluorescence of cytoskeletal components, focal adhesion assay, migration assay","journal":"The international journal of biochemistry & cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — substrate cleavage demonstrated, phenotype validated with genetic null cells, multiple orthogonal readouts","pmids":["18775505"],"is_preprint":false},{"year":2009,"finding":"ADAMTS1 and MMP1 orchestrate a paracrine signaling cascade in bone metastasis: they proteolytically release membrane-bound EGF-like growth factors (AREG, HB-EGF, TGFα) from tumor cells, which suppress OPG expression in osteoblasts and potentiate osteoclast differentiation, promoting osteolytic bone metastasis. EGFR inhibitors block this cascade in bone stromal cells.","method":"Gain-of-function in tumor cell lines, conditioned medium transfer to osteoblasts, EGFR inhibitor treatment, osteoclast differentiation assay, bone metastasis mouse model","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-step paracrine pathway validated in vitro and in vivo with mechanistic inhibitor experiments","pmids":["19608765"],"is_preprint":false},{"year":2009,"finding":"ADAMTS1 cleaves semaphorin 3C, releasing it from the extracellular matrix, and this cleavage promotes migration of breast cancer cells. Identified by two complementary proteomics approaches (DIGE and SILAC).","method":"DIGE and SILAC proteomics, recombinant ADAMTS1 overexpression, mass spectrometry substrate identification, breast cancer cell migration assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — two orthogonal proteomics approaches, functional migration readout, single lab","pmids":["19915008"],"is_preprint":false},{"year":2009,"finding":"Hypoxia transiently induces ADAMTS1 mRNA and protein specifically in endothelial cells (not other cell types) via HIF-1 binding to at least three HIF binding sites in the ADAMTS1 promoter, as confirmed by chromatin immunoprecipitation. This induction is blocked by PI3K inhibitor LY294002. Recombinant ADAMTS1 promotes HUVEC migration under hypoxic conditions.","method":"Hypoxia and CoCl2 treatment, real-time PCR, Western blot, promoter-luciferase assay, chromatin immunoprecipitation (ChIP), PI3K inhibitor, cell migration assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP confirms HIF-1 binding, PI3K-dependence shown pharmacologically, functional migration readout; single lab with multiple methods","pmids":["19349275"],"is_preprint":false},{"year":2010,"finding":"ADAMTS1 cleaves thrombospondin-1 (TSP1), and this cleavage is organ-context-dependent: cleavage occurs more efficiently in liver than lung lysates, and ADAMTS1 inhibition (neutralizing antibody, siRNA, or genetic deletion) abrogates TSP1 cleavage. Differential ADAMTS1-mediated TSP1 processing underlies the variable anti-metastatic efficacy of TSP1 in liver vs. lung. [Note: this paper was retracted.]","method":"TSP1 cleavage assay in liver vs. lung lysates, neutralizing antibody, siRNA knockdown, Adamts1 knockout mice, metastasis models","journal":"Cancer research","confidence":"Low","confidence_rationale":"Tier 2 / Weak — paper was subsequently retracted; findings cannot be relied upon","pmids":["20103648"],"is_preprint":false},{"year":2011,"finding":"ADAMTS1 is required for mammary tumor growth and metastasis in vivo: Adamts1 knockout in the MMTV-PyMT mouse model significantly reduces tumor burden and lung metastasis, with increased apoptosis and increased cytotoxic immune cell activation. Adamts1-null tumor stroma shows less proteolytically cleaved versican and increased CD45+ leukocyte infiltration.","method":"Adamts1 knockout mouse crossed with MMTV-PyMT mammary tumor model, histology, apoptosis assay, versican neoepitope immunostaining, immune cell phenotyping (IL-12, CD45)","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined in vivo phenotypic readouts, substrate cleavage, and immune cell characterization","pmids":["22001177"],"is_preprint":false},{"year":2012,"finding":"In kidney pericytes, ADAMTS1 expression is rapidly activated after injury and contributes to microvascular destabilization, while TIMP3 (its inhibitor) stabilizes capillary tube networks. TIMP3-null mice show spontaneous microvascular phenotype with overactivated pericytes and increased susceptibility to injury-stimulated microvascular rarefaction.","method":"Gene expression profiling in kidney pericytes in vivo, 3D capillary tube assay, Timp3 knockout mouse, pericyte differentiation experiments","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gene activation, functional 3D tube assay, and genetic KO validation","pmids":["22383695"],"is_preprint":false},{"year":2013,"finding":"ADAMTS1 acts as a tumor suppressor in breast cancer xenografts by cleaving nidogen-1 and nidogen-2 from vascular basement membranes, disrupting vessel morphology and reducing vessel density. Increased ADAMTS1 expression causes near-complete inhibition of tumor growth and correlates with nidogen cleavage.","method":"Xenograft tumor model, ADAMTS1 overexpression, immunostaining for nidogens and vessels, microvessel density quantification","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo xenograft with functional substrate (nidogen) cleavage readout, single lab","pmids":["23681936"],"is_preprint":false},{"year":2014,"finding":"ADAMTS1 inhibits lymphangiogenesis by forming a complex with VEGF-C and attenuating phosphorylation of VEGFR3 in lymphatic endothelial cells. Immunoprecipitation assays confirmed ADAMTS1-VEGF-C complex formation.","method":"Adenoviral ADAMTS1 gene transduction of lymphatic endothelial cells, cell proliferation assay, tube formation assay, migration assay, VEGFR3 phosphorylation assay, co-immunoprecipitation","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP confirms complex, functional VEGFR3 phosphorylation readout, single lab","pmids":["24631293"],"is_preprint":false},{"year":2016,"finding":"ADAMTS1 is required for SPARC-induced collagen deposition in aging myocardium. SPARC stimulation of cardiac fibroblasts increases secretion of both latent (110 kDa) and active (87 kDa) ADAMTS1 forms and promotes collagen I secretion; an ADAMTS1 blocking antibody suppresses SPARC-induced collagen I secretion. ADAMTS1 substrate versican decreases with age only in wild-type mice (not SPARC-null), linking SPARC-ADAMTS1 to proteoglycan turnover.","method":"SPARC-null mice, cardiac fibroblast stimulation with SPARC, ADAMTS1 blocking antibody, Western blot, picrosirius red staining, versican immunostaining","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — blocking antibody functional validation and SPARC-null mouse genetic evidence, single lab","pmids":["27143554"],"is_preprint":false},{"year":2016,"finding":"Adamts1 metalloprotease activity impairs adipocyte commitment by remodeling ECM components and activating FAK-ERK signaling. miR-181d targets and represses Adamts1 to permit adipocytic lineage commitment. Ablation of Adamts1 in adipose tissue increases adipose mass and disrupts lipid homeostasis. The catalytic activity of Adamts1 is required for this inhibitory effect.","method":"Forced expression and siRNA knockdown of Adamts1, catalytic domain mutagenesis, adipogenesis differentiation assay, FAK-ERK signaling analysis, adipose-specific Adamts1 knockout mice, miR-181d target validation","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytic mutant distinguishes protease-dependent mechanism, KO mice, multiple signaling readouts, miRNA-target validation","pmids":["27447109"],"is_preprint":false},{"year":2017,"finding":"Macrophage-derived ADAMTS1 promotes satellite cell (muscle stem cell) activation by cleaving NOTCH1, thereby reducing Notch signaling. Overexpression of Adamts1 in macrophages in vivo is sufficient to increase satellite cell activation and improve muscle regeneration. NOTCH1 is identified as a direct substrate of ADAMTS1 metalloproteinase activity.","method":"Macrophage-specific Adamts1 overexpression in vivo, satellite cell activation assay, Notch signaling analysis, NOTCH1 substrate cleavage assay, muscle injury model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — substrate identified, in vivo overexpression with defined cellular phenotype, Notch signaling mechanistic readout","pmids":["28939843"],"is_preprint":false},{"year":2017,"finding":"Genetic haploinsufficiency of Adamts1 in mice causes thoracic aortic aneurysm and dissection (TAAD) associated with elevated aortic nitric oxide and Nos2 levels. Nos2 inactivation or pharmacological NOS2 inhibition protects Adamts1-deficient mice from aortic pathology and rapidly reverses aortic dilation and medial degeneration, placing ADAMTS1 upstream of the NOS2 axis in vascular homeostasis.","method":"Adamts1 haploinsufficient mice, Nos2 genetic knockout, NOS2 pharmacological inhibition, aortic histology and diameter measurement, nitric oxide quantification","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double mutant), pharmacological rescue, mechanistic pathway placement","pmids":["28067899"],"is_preprint":false},{"year":2020,"finding":"ADAMTS1 and syndecan-4 are functionally interconnected in regulating endothelial cell adhesion, migration, and angiogenesis. Knockdown of ADAMTS1 in endothelial cells reduces cell-surface syndecan-4 levels via increased MMP9 activity. Both ADAMTS1 and syndecan-4 knockdowns enhance VEGFA164 responses and aortic ring sprouting. Fibulin-1, an ADAMTS1 co-factor, is absent from conditioned matrix of knockdown cells and correlates with altered migration.","method":"siRNA knockdown of ADAMTS1 and syndecan-4, MMP9 activity assay, VEGFA response assay, ex vivo aortic ring sprouting, conditioned matrix experiment, fibulin-1 expression analysis","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple siRNA knockdowns with parallel functional readouts, matrix-dependent phenotype confirmed, single lab","pmids":["32269093"],"is_preprint":false},{"year":2021,"finding":"ADAMTS1 cleaves versican V1 at the canonical Glu441-Ala442 site and at multiple additional sites (21 novel sites with a P1-Glu preference), as determined by label-free quantitative LC-MS/MS proteomics comparing active vs. catalytically inactive ADAMTS1 digests of purified versican V1.","method":"In vitro digestion of recombinant versican V1 with recombinant ADAMTS1 vs. catalytically inactive mutant, LC-MS/MS, semi-tryptic peptide z-score analysis","journal":"Journal of proteomics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins, catalytically inactive control, mass spectrometry site mapping","pmids":["34450332"],"is_preprint":false},{"year":2006,"finding":"VEGF upregulates ADAMTS1 expression in endothelial cells via VEGFR2 → phospholipase C-gamma → PKCbeta signaling. Knockdown of endogenous ADAMTS1 by siRNA increases endothelial cell proliferation, indicating ADAMTS1 is an endogenous brake on endothelial proliferation downstream of VEGF.","method":"VEGF stimulation, VEGFR2 and PLC-gamma inhibitors, PKC inhibitors (calphostin C, PKCbeta-specific inhibitor), siRNA knockdown, [3H]-thymidine incorporation proliferation assay","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological pathway dissection with multiple specific inhibitors, siRNA loss-of-function, functional proliferation readout","pmids":["16936124"],"is_preprint":false},{"year":2008,"finding":"HDAC6 and SP1 repress ADAMTS1 transcription via proximal GC-box elements. HDAC inhibitors (TSA, SAHA) and HDAC6-specific inhibitor tubacin upregulate ADAMTS1 expression. ChIP and DAPA assays confirm decreased SP1 and HDAC6 binding to the ADAMTS1 promoter after TSA treatment.","method":"Promoter-luciferase reporter assay, ChIP (chromatin immunoprecipitation), DAPA (DNA affinity precipitation assay), HDAC inhibitors, HDAC6 knockdown, SP1 analysis","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and DAPA confirm direct binding, pharmacological and siRNA evidence, single lab","pmids":["19007777"],"is_preprint":false},{"year":2015,"finding":"Ethanol increases O-GlcNAc modification of Adamts1 and decreases its interaction with endogenous inhibitor TIMP3 in myocytes, leading to increased collagen I and decreased elastin. Silencing Adamts1 by siRNA blocks ethanol-induced collagen/elastin changes. This is controlled upstream by FoxO1-sestrin3-AMPK signaling.","method":"siRNA knockdown of Adamts1, MMP pharmacological inhibition, O-GlcNAc modification detection, TIMP3 co-immunoprecipitation, FoxO1/AMPK pathway inhibitors, collagen/elastin quantification in C2C12 myocytes","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA and pharmacological inhibition with pathway dissection, single lab, single cell type","pmids":["25142777"],"is_preprint":false}],"current_model":"ADAMTS1 is a secreted zinc metalloprotease activated by furin-mediated prodomain removal (and further processed by MMPs) that cleaves extracellular matrix substrates including aggrecan, versican, nidogen-1/2, syndecan-4, semaphorin 3C, TFPI-2, and NOTCH1; sequesters VEGF165 and VEGF-C via its C-terminal thrombospondin repeats to suppress VEGFR2 and VEGFR3 phosphorylation; is regulated transcriptionally by HIF-1, LH/PR, VEGF-PKCβ, and HDAC6/SP1; functions in vascular homeostasis through an ADAMTS1-NOS2 axis; and plays context-dependent roles in ovulation, myocardial trabeculation, muscle stem cell activation via Notch cleavage, adipogenesis, and tumor progression."},"narrative":{"mechanistic_narrative":"ADAMTS1 (METH-1) is a secreted, extracellular-matrix-associated zinc metalloprotease that remodels the pericellular matrix and modulates angiogenic and morphogenetic signaling, establishing it as an anti-angiogenic and matrix-remodeling factor [PMID:10438512, PMID:10373500]. It is produced as a latent proenzyme that is activated by furin-mediated prodomain removal in the secretory pathway, then further processed by MMP-2/8/15 at its C-terminus to generate a p65 form that loses two thrombospondin repeats, reduced heparin affinity, and reduced anti-proliferative activity [PMID:10373500, PMID:10944521]; catalysis depends on an intact zinc-binding motif and is restrained by TIMP-2 and TIMP-3 [PMID:12054629]. Through its proteolytic activity ADAMTS1 cleaves an extensive set of matrix and cell-surface substrates including aggrecan, versican (generating the DPEAAE neoepitope), nidogen-1/2, syndecan-4, semaphorin 3C, TFPI-2, and NOTCH1, and sheds membrane-bound EGF-family ligands (HB-EGF, amphiregulin, TGFα) [PMID:12054629, PMID:12907688, PMID:16511810, PMID:18775505, PMID:19915008, PMID:28939843, PMID:16314835, PMID:34450332]; fibulin-1 acts as a cofactor that enhances aggrecan cleavage [PMID:16061471]. Independent of catalysis, ADAMTS1 sequesters the heparin-binding forms of VEGF165 and VEGF-C via its C-terminal thrombospondin repeats to suppress VEGFR2 and VEGFR3 phosphorylation and endothelial/lymphatic proliferation [PMID:12716911, PMID:24631293]. Its expression is tightly controlled: induced by LH/cAMP/PKA and progesterone receptor in ovulating granulosa cells [PMID:15256533], by hypoxia through HIF-1 in endothelial cells [PMID:19349275], and downstream of VEGF–VEGFR2–PLCγ–PKCβ signaling [PMID:16936124], and repressed by HDAC6/SP1 [PMID:19007777]. These activities translate into context-dependent physiological roles in ovulation through versican cleavage [PMID:12907688], cardiac trabeculation through cardiac jelly degradation [PMID:18267097], muscle stem cell activation through NOTCH1 cleavage [PMID:28939843], adipocyte commitment via FAK-ERK signaling [PMID:27447109], vascular homeostasis through an ADAMTS1–NOS2 axis whose disruption causes thoracic aortic aneurysm [PMID:28067899], and both pro- and anti-tumorigenic effects in breast, bone, and pulmonary metastasis [PMID:16314835, PMID:19608765, PMID:22001177, PMID:23681936].","teleology":[{"year":1999,"claim":"Establishing that the protein is a genuine secreted enzyme and an anti-angiogenic factor defined the foundational identity of ADAMTS1.","evidence":"Recombinant protein in endothelial proliferation, cornea pocket, and CAM assays; alpha2-macroglobulin trapping, zinc-motif mutagenesis, and furin-deficient cell complementation","pmids":["10438512","10373500"],"confidence":"High","gaps":["In vivo physiological substrate(s) not yet identified","Mechanism of anti-angiogenesis (proteolytic vs. binding) not resolved at this stage"]},{"year":2000,"claim":"Defining sequential furin then MMP processing showed activation and maturation generate functionally distinct forms, explaining how proteolytic state tunes activity.","evidence":"Furin/MMP inhibitors and purified enzymes, heparin affinity chromatography, endothelial proliferation readout","pmids":["10944521"],"confidence":"High","gaps":["Physiological trigger for C-terminal processing in vivo unclear","Functional role of the released C-terminal TSR fragments not defined here"]},{"year":2002,"claim":"Identifying ADAMTS1 as an aggrecanase with defined inhibitor sensitivity placed it in matrix proteoglycan turnover.","evidence":"In vitro ECM protease assays, zinc-motif and furin-site mutants, TIMP-2/3 and monoclonal antibody inhibition","pmids":["12054629"],"confidence":"High","gaps":["Physiological relevance of aggrecan cleavage in tissue not established","Substrate repertoire beyond aggrecan not yet mapped"]},{"year":2003,"claim":"Discovery of direct VEGF165 sequestration via the C-terminal region revealed a catalysis-independent mechanism for anti-angiogenesis.","evidence":"Co-IP, cross-linking, domain deletion, VEGFR2 phosphorylation assay, tumor extract validation","pmids":["12716911"],"confidence":"High","gaps":["Relative contribution of sequestration vs. proteolysis to angiogenesis in vivo unclear","Reversibility implications for tissue VEGF bioavailability untested"]},{"year":2003,"claim":"Demonstrating ovary-specific versican cleavage and subcellular trafficking linked ADAMTS1 proteolysis to a defined physiological process, ovulation.","evidence":"Domain-specific antibodies, immunofluorescence, versican neoepitope detection, PRKO mouse","pmids":["12907688"],"confidence":"High","gaps":["Whether versican cleavage alone is sufficient for COC expansion not established"]},{"year":2004,"claim":"Mapping the LH/cAMP/PKA and PR-coregulated promoter explained how ADAMTS1 is transcriptionally induced during ovulation.","evidence":"Promoter-luciferase truncation/mutant constructs, PR antagonist, PRA/PRB co-transfection, cAMP analogs in granulosa cells","pmids":["15256533"],"confidence":"High","gaps":["How PR acts without a consensus PRE not mechanistically resolved","Generality of this regulation outside granulosa cells unknown"]},{"year":2005,"claim":"Identifying fibulin-1 as a binding cofactor that enhances aggrecan cleavage showed ADAMTS1 activity is modulated by ECM partners.","evidence":"Yeast two-hybrid, affinity chromatography, co-IP, pulldown, ELISA, in vitro aggrecan cleavage","pmids":["16061471"],"confidence":"High","gaps":["Structural basis of fibulin-1-mediated enhancement unknown","Whether fibulin-1 modulates other substrates not tested"]},{"year":2005,"claim":"Demonstrating concentration-dependent dual control of cell migration (proteolytic stimulation vs. FGF-2 sequestration) revealed ADAMTS1 as a context-dependent migration regulator in wound healing.","evidence":"Wound-tissue immunofluorescence, KO mouse skin, migration assays with recombinant/protease-dead protein, FGF-2 binding","pmids":["15843381"],"confidence":"High","gaps":["Local concentration thresholds in tissue not defined","FGF-2 sequestration domain not precisely mapped"]},{"year":2006,"claim":"Expanding the substrate set (TFPI-2, nidogen-1/2 and other proteomics hits) and defining VEGF-driven induction broadened both the enzymatic repertoire and upstream regulation of ADAMTS1.","evidence":"Yeast two-hybrid plus biochemical cleavage; DIGE/MS with immunochemical validation; VEGF stimulation with VEGFR2/PLCγ/PKC inhibitors and siRNA","pmids":["16641089","16511810","16936124"],"confidence":"High","gaps":["Physiological significance of TFPI-2 and nidogen cleavage in tissue not established","Several DIGE-identified substrates remain unvalidated"]},{"year":2008,"claim":"Identifying syndecan-4 cleavage, HDAC6/SP1 repression, and Brg1-controlled cardiac repression connected ADAMTS1 to cytoskeletal/adhesion control, epigenetic regulation, and heart morphogenesis.","evidence":"Recombinant cleavage with syndecan-4 null cells and focal adhesion/migration assays; promoter-luciferase, ChIP, DAPA with HDAC inhibitors; Brg1 conditional endocardial KO with cardiac phenotyping","pmids":["18775505","19007777","18267097"],"confidence":"High","gaps":["How a single protease coordinates these distinct outputs in vivo unclear","HDAC6/SP1 repression evidence from a single lab"]},{"year":2009,"claim":"Linking ADAMTS1 to EGF-ligand shedding, semaphorin 3C cleavage, paracrine bone metastasis, and HIF-1 hypoxic induction defined its proteolytic role in tumor signaling and stress-responsive expression.","evidence":"WT vs. protease-dead overexpression and metastasis models; DIGE/SILAC proteomics with migration assays; conditioned-medium transfer to osteoblasts with EGFR inhibitors; hypoxia/ChIP with HIF-1 binding sites","pmids":["16314835","19915008","19608765","19349275"],"confidence":"High","gaps":["Reconciling pro- vs. anti-tumor roles across contexts not resolved","Semaphorin 3C cleavage from a single lab"]},{"year":2011,"claim":"Genetic loss in a mammary tumor model showed ADAMTS1 is required for tumor growth and metastasis and shapes the immune/versican tumor microenvironment.","evidence":"Adamts1 KO crossed with MMTV-PyMT, histology, apoptosis, versican neoepitope, CD45/IL-12 immune phenotyping","pmids":["22001177"],"confidence":"High","gaps":["Whether immune effects are downstream of versican cleavage not directly tested"]},{"year":2012,"claim":"Implicating ADAMTS1 in pericyte-driven microvascular destabilization opposed by TIMP3 extended its vascular role to injury-induced rarefaction.","evidence":"In vivo pericyte expression profiling, 3D capillary tube assay, Timp3 KO mouse","pmids":["22383695"],"confidence":"High","gaps":["Substrate mediating destabilization not identified"]},{"year":2014,"claim":"Showing VEGF-C sequestration that suppresses VEGFR3 generalized the C-terminal ligand-trapping mechanism to lymphangiogenesis.","evidence":"Adenoviral ADAMTS1 in lymphatic endothelial cells, proliferation/tube/migration assays, VEGFR3 phosphorylation, co-IP","pmids":["24631293"],"confidence":"Medium","gaps":["Single Co-IP; in vivo relevance to lymphatic biology untested"]},{"year":2013,"claim":"Defining nidogen cleavage that disrupts vascular basement membranes assigned ADAMTS1 a tumor-suppressive anti-angiogenic mechanism in breast xenografts.","evidence":"Xenograft with ADAMTS1 overexpression, nidogen and vessel immunostaining, microvessel density","pmids":["23681936"],"confidence":"Medium","gaps":["Single lab; contrasts with pro-metastatic roles in other models"]},{"year":2016,"claim":"Distinguishing protease-dependent control of adipocyte commitment and SPARC-driven cardiac collagen deposition refined ADAMTS1's roles in lineage commitment and cardiac matrix remodeling.","evidence":"Catalytic mutant, adipose-specific KO, FAK-ERK readouts, miR-181d targeting; SPARC-null mice, fibroblast stimulation, blocking antibody, versican immunostaining","pmids":["27447109","27143554"],"confidence":"High","gaps":["Direct ECM substrate driving adipocyte FAK-ERK signaling not pinpointed","SPARC-ADAMTS1 collagen link from a single lab"]},{"year":2017,"claim":"Identifying NOTCH1 as a direct substrate for muscle stem cell activation and placing ADAMTS1 upstream of the NOS2 vascular axis (aortic aneurysm) demonstrated specific in vivo signaling and disease mechanisms.","evidence":"Macrophage-specific Adamts1 overexpression with NOTCH1 cleavage/satellite cell assays; Adamts1 haploinsufficient mice with Nos2 KO and pharmacological NOS2 inhibition","pmids":["28939843","28067899"],"confidence":"High","gaps":["How NOS2 is regulated downstream of ADAMTS1 not molecularly defined","Substrate connecting ADAMTS1 loss to NOS2 elevation unidentified"]},{"year":2020,"claim":"Connecting ADAMTS1, syndecan-4, MMP9, and fibulin-1 in endothelial adhesion and VEGFA responses integrated several earlier partners into one angiogenic regulatory network.","evidence":"siRNA knockdowns, MMP9 activity, VEGFA response, aortic ring sprouting, conditioned matrix and fibulin-1 analysis","pmids":["32269093"],"confidence":"Medium","gaps":["Causality among the network nodes incompletely resolved","Single lab"]},{"year":2021,"claim":"High-resolution mapping of versican V1 cleavage sites with a catalytically inactive control provided definitive enzymatic characterization of a principal substrate.","evidence":"In vitro digestion of recombinant versican V1, active vs. inactive ADAMTS1, label-free LC-MS/MS","pmids":["34450332"],"confidence":"High","gaps":["Biological role of the 21 novel cleavage sites in tissue not tested"]},{"year":null,"claim":"How ADAMTS1's many context-dependent roles (pro- vs. anti-angiogenic, pro- vs. anti-tumor) are selected by tissue, processing state, cofactor availability, and substrate context remains the central unresolved question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying framework reconciling opposing phenotypes","Relative in vivo contributions of catalytic vs. ligand-sequestering activities unquantified","Structural basis of substrate and cofactor selectivity unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,5,10,13,15,24,27]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,2,3]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[4,21,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,21]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,5]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[1,5,20]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[3,5,13,20,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,11,14,24,28]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,14,18,25]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,24]}],"complexes":[],"partners":["FBLN1","VEGFA","VEGFC","TIMP3","TIMP2","SDC4","A2M"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UHI8","full_name":"A disintegrin and metalloproteinase with thrombospondin motifs 1","aliases":["METH-1"],"length_aa":967,"mass_kda":105.4,"function":"Metalloprotease which cleaves aggrecan, a cartilage proteoglycan, at the '1938-Glu-|-Leu-1939' site (within the chondroitin sulfate attachment domain), and may be involved in its turnover (By similarity). Also cleaves COMP (PubMed:39672391). Has angiogenic inhibitor activity (PubMed:10438512). May play a critical role in follicular rupture (By similarity)","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q9UHI8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADAMTS1","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HSP90B1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ADAMTS1","total_profiled":1310},"omim":[{"mim_id":"616020","title":"CYSTEINE/TYROSINE-RICH PROTEIN 1; CYYR1","url":"https://www.omim.org/entry/616020"},{"mim_id":"614545","title":"ENDOPLASMIC RETICULUM MEMBRANE PROTEIN COMPLEX, SUBUNIT 10; EMC10","url":"https://www.omim.org/entry/614545"},{"mim_id":"611681","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 20; ADAMTS20","url":"https://www.omim.org/entry/611681"},{"mim_id":"610113","title":"ADAMTS-LIKE PROTEIN 4; ADAMTSL4","url":"https://www.omim.org/entry/610113"},{"mim_id":"609198","title":"ADAMTS-LIKE PROTEIN 1; ADAMTSL1","url":"https://www.omim.org/entry/609198"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Plasma membrane","reliability":"Uncertain"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"ovary","ntpm":367.9}],"url":"https://www.proteinatlas.org/search/ADAMTS1"},"hgnc":{"alias_symbol":["C3-C5","METH1","KIAA1346"],"prev_symbol":[]},"alphafold":{"accession":"Q9UHI8","domains":[{"cath_id":"3.40.390.10","chopping":"255-476","consensus_level":"high","plddt":91.4256,"start":255,"end":476},{"cath_id":"3.40.1620.60","chopping":"490-556","consensus_level":"high","plddt":87.2658,"start":490,"end":556},{"cath_id":"-","chopping":"622-699","consensus_level":"medium","plddt":84.1901,"start":622,"end":699},{"cath_id":"2.60.120.830","chopping":"725-844","consensus_level":"high","plddt":87.9033,"start":725,"end":844},{"cath_id":"-","chopping":"857-905","consensus_level":"high","plddt":84.6673,"start":857,"end":905},{"cath_id":"2.20.100","chopping":"912-964","consensus_level":"high","plddt":83.5038,"start":912,"end":964},{"cath_id":"2.40.128","chopping":"56-95_123-162","consensus_level":"medium","plddt":83.7786,"start":56,"end":162}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UHI8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UHI8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UHI8-F1-predicted_aligned_error_v6.png","plddt_mean":77.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADAMTS1","jax_strain_url":"https://www.jax.org/strain/search?query=ADAMTS1"},"sequence":{"accession":"Q9UHI8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UHI8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UHI8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UHI8"}},"corpus_meta":[{"pmid":"10438512","id":"PMC_10438512","title":"METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10438512","citation_count":351,"is_preprint":false},{"pmid":"19608765","id":"PMC_19608765","title":"ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.","date":"2009","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/19608765","citation_count":248,"is_preprint":false},{"pmid":"458145","id":"PMC_458145","title":"The alternative pathway C3/C5 convertase: chemical basis of factor B activation.","date":"1979","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/458145","citation_count":231,"is_preprint":false},{"pmid":"12907688","id":"PMC_12907688","title":"Processing and localization of ADAMTS-1 and proteolytic cleavage of versican during cumulus matrix expansion and ovulation.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12907688","citation_count":222,"is_preprint":false},{"pmid":"18267097","id":"PMC_18267097","title":"Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis.","date":"2008","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/18267097","citation_count":207,"is_preprint":false},{"pmid":"12716911","id":"PMC_12716911","title":"ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12716911","citation_count":205,"is_preprint":false},{"pmid":"978134","id":"PMC_978134","title":"Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.","date":"1976","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/978134","citation_count":193,"is_preprint":false},{"pmid":"12054629","id":"PMC_12054629","title":"ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12054629","citation_count":192,"is_preprint":false},{"pmid":"22383695","id":"PMC_22383695","title":"Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury.","date":"2012","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/22383695","citation_count":169,"is_preprint":false},{"pmid":"28067899","id":"PMC_28067899","title":"Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28067899","citation_count":148,"is_preprint":false},{"pmid":"18272597","id":"PMC_18272597","title":"Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor.","date":"2008","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18272597","citation_count":145,"is_preprint":false},{"pmid":"10944521","id":"PMC_10944521","title":"Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10944521","citation_count":133,"is_preprint":false},{"pmid":"16314835","id":"PMC_16314835","title":"Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16314835","citation_count":131,"is_preprint":false},{"pmid":"10373500","id":"PMC_10373500","title":"ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10373500","citation_count":131,"is_preprint":false},{"pmid":"21948367","id":"PMC_21948367","title":"Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis.","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/21948367","citation_count":129,"is_preprint":false},{"pmid":"30953539","id":"PMC_30953539","title":"Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood.","date":"2019","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/30953539","citation_count":126,"is_preprint":false},{"pmid":"17167179","id":"PMC_17167179","title":"ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis.","date":"2006","source":"Cellular oncology : the official journal of the International Society for Cellular Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17167179","citation_count":124,"is_preprint":false},{"pmid":"17383432","id":"PMC_17383432","title":"Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice.","date":"2007","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17383432","citation_count":120,"is_preprint":false},{"pmid":"28939843","id":"PMC_28939843","title":"Macrophage-released ADAMTS1 promotes muscle stem cell activation.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28939843","citation_count":110,"is_preprint":false},{"pmid":"15256533","id":"PMC_15256533","title":"Coordinate transcription of the ADAMTS-1 gene by luteinizing hormone and progesterone receptor.","date":"2004","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15256533","citation_count":106,"is_preprint":false},{"pmid":"21860027","id":"PMC_21860027","title":"Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21860027","citation_count":105,"is_preprint":false},{"pmid":"16061471","id":"PMC_16061471","title":"Fibulin-1 acts as a cofactor for the matrix metalloprotease ADAMTS-1.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16061471","citation_count":90,"is_preprint":false},{"pmid":"12814950","id":"PMC_12814950","title":"ADAMTS1: a matrix metalloprotease with angioinhibitory properties.","date":"2003","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12814950","citation_count":88,"is_preprint":false},{"pmid":"19915008","id":"PMC_19915008","title":"The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19915008","citation_count":87,"is_preprint":false},{"pmid":"15599946","id":"PMC_15599946","title":"The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican.","date":"2005","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15599946","citation_count":87,"is_preprint":false},{"pmid":"11705860","id":"PMC_11705860","title":"Expression of METH-1 and METH-2 in pancreatic cancer.","date":"2001","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11705860","citation_count":84,"is_preprint":false},{"pmid":"3032341","id":"PMC_3032341","title":"Long C3-C5 propriospinal neurones in the cat.","date":"1987","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/3032341","citation_count":82,"is_preprint":false},{"pmid":"23245439","id":"PMC_23245439","title":"ADAMTS-1 and ADAMTS-4 levels are elevated in thoracic aortic aneurysms and dissections.","date":"2012","source":"The Annals of thoracic surgery","url":"https://pubmed.ncbi.nlm.nih.gov/23245439","citation_count":72,"is_preprint":false},{"pmid":"23444028","id":"PMC_23444028","title":"The metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways.","date":"2013","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23444028","citation_count":67,"is_preprint":false},{"pmid":"18775505","id":"PMC_18775505","title":"Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion.","date":"2008","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18775505","citation_count":67,"is_preprint":false},{"pmid":"30083158","id":"PMC_30083158","title":"Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30083158","citation_count":64,"is_preprint":false},{"pmid":"20598569","id":"PMC_20598569","title":"Increased expression of HIF-1alpha, VEGF-A and its receptors, MMP-2, TIMP-1, and ADAMTS-1 at the venous stenosis of arteriovenous fistula in a mouse model with renal insufficiency.","date":"2010","source":"Journal of vascular and interventional radiology : JVIR","url":"https://pubmed.ncbi.nlm.nih.gov/20598569","citation_count":64,"is_preprint":false},{"pmid":"22001177","id":"PMC_22001177","title":"The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22001177","citation_count":63,"is_preprint":false},{"pmid":"7350230","id":"PMC_7350230","title":"The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.","date":"1980","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7350230","citation_count":63,"is_preprint":false},{"pmid":"19349275","id":"PMC_19349275","title":"ADAMTS1 is a unique hypoxic early response gene expressed by endothelial cells.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19349275","citation_count":62,"is_preprint":false},{"pmid":"15843381","id":"PMC_15843381","title":"ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15843381","citation_count":62,"is_preprint":false},{"pmid":"9441751","id":"PMC_9441751","title":"The exon/intron organization and chromosomal mapping of the mouse ADAMTS-1 gene encoding an ADAM family protein with TSP motifs.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9441751","citation_count":62,"is_preprint":false},{"pmid":"19553617","id":"PMC_19553617","title":"Differential effects of ADAMTS-1, -4, and -5 in the trabecular meshwork.","date":"2009","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19553617","citation_count":61,"is_preprint":false},{"pmid":"12049787","id":"PMC_12049787","title":"Expression of ADAMTS1 during murine development.","date":"2002","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/12049787","citation_count":59,"is_preprint":false},{"pmid":"16630594","id":"PMC_16630594","title":"ADAMTS-1 and -4 are up-regulated following transient middle cerebral artery occlusion in the rat and their expression is modulated by TNF in cultured astrocytes.","date":"2006","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16630594","citation_count":57,"is_preprint":false},{"pmid":"19010931","id":"PMC_19010931","title":"ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19010931","citation_count":57,"is_preprint":false},{"pmid":"16511810","id":"PMC_16511810","title":"Identification of substrates of the extracellular protease ADAMTS1 by DIGE proteomic analysis.","date":"2006","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/16511810","citation_count":53,"is_preprint":false},{"pmid":"15983115","id":"PMC_15983115","title":"Expression of versican and ADAMTS1, 4, and 5 during bone development in the rat mandible and hind limb.","date":"2005","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/15983115","citation_count":51,"is_preprint":false},{"pmid":"16641089","id":"PMC_16641089","title":"ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16641089","citation_count":51,"is_preprint":false},{"pmid":"23289900","id":"PMC_23289900","title":"Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion.","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23289900","citation_count":51,"is_preprint":false},{"pmid":"32719126","id":"PMC_32719126","title":"Bacterial synthesis of C3-C5 diols via extending amino acid catabolism.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32719126","citation_count":49,"is_preprint":false},{"pmid":"16947020","id":"PMC_16947020","title":"Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy.","date":"2006","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/16947020","citation_count":49,"is_preprint":false},{"pmid":"23859810","id":"PMC_23859810","title":"Regulation of ADAMTS-1, -4 and -5 expression in human macrophages: differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17.","date":"2013","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/23859810","citation_count":49,"is_preprint":false},{"pmid":"11108265","id":"PMC_11108265","title":"ADAMTS-1: A cellular disintegrin and metalloprotease with thrombospondin motifs is a target for parathyroid hormone in bone.","date":"2000","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11108265","citation_count":49,"is_preprint":false},{"pmid":"27143554","id":"PMC_27143554","title":"Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium.","date":"2016","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27143554","citation_count":48,"is_preprint":false},{"pmid":"20103648","id":"PMC_20103648","title":"RETRACTED: Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20103648","citation_count":48,"is_preprint":false},{"pmid":"15625312","id":"PMC_15625312","title":"Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction.","date":"2004","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15625312","citation_count":45,"is_preprint":false},{"pmid":"20655981","id":"PMC_20655981","title":"ADAMTS-1: a new human ovulatory gene and a cumulus marker for fertilization capacity.","date":"2010","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20655981","citation_count":44,"is_preprint":false},{"pmid":"16936124","id":"PMC_16936124","title":"Vascular endothelial growth factor upregulates expression of ADAMTS1 in endothelial cells through protein kinase C signaling.","date":"2006","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/16936124","citation_count":43,"is_preprint":false},{"pmid":"14664708","id":"PMC_14664708","title":"Regulation of transcripts encoding ADAMTS-1 (a disintegrin and metalloproteinase with thrombospondin-like motifs-1) and progesterone receptor by human chorionic gonadotropin in equine preovulatory follicles.","date":"2003","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/14664708","citation_count":43,"is_preprint":false},{"pmid":"2917424","id":"PMC_2917424","title":"A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.","date":"1989","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/2917424","citation_count":42,"is_preprint":false},{"pmid":"34439277","id":"PMC_34439277","title":"Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34439277","citation_count":40,"is_preprint":false},{"pmid":"16675485","id":"PMC_16675485","title":"Differential effects of interleukin-1beta and transforming growth factor-beta1 on the expression of the inflammation-associated protein, ADAMTS-1, in human decidual stromal cells in vitro.","date":"2006","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16675485","citation_count":40,"is_preprint":false},{"pmid":"32269093","id":"PMC_32269093","title":"ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis.","date":"2020","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/32269093","citation_count":39,"is_preprint":false},{"pmid":"18174457","id":"PMC_18174457","title":"Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.","date":"2008","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18174457","citation_count":39,"is_preprint":false},{"pmid":"23562508","id":"PMC_23562508","title":"ADAMTS1, ADAMTS5, ADAMTS9 and aggrecanase-generated proteoglycan fragments are induced following spinal cord injury in mouse.","date":"2013","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/23562508","citation_count":39,"is_preprint":false},{"pmid":"24646063","id":"PMC_24646063","title":"Evidence for decreased expression of ADAMTS-1 associated with impaired oocyte quality in PCOS patients.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24646063","citation_count":39,"is_preprint":false},{"pmid":"34450332","id":"PMC_34450332","title":"Identification of novel ADAMTS1, ADAMTS4 and ADAMTS5 cleavage sites in versican using a label-free quantitative proteomics approach.","date":"2021","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/34450332","citation_count":38,"is_preprint":false},{"pmid":"23681936","id":"PMC_23681936","title":"Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2.","date":"2013","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23681936","citation_count":38,"is_preprint":false},{"pmid":"28890348","id":"PMC_28890348","title":"MiR-362-3p inhibits the proliferation and migration of vascular smooth muscle cells in atherosclerosis by targeting ADAMTS1.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28890348","citation_count":38,"is_preprint":false},{"pmid":"26124221","id":"PMC_26124221","title":"The ADAMTS1 Gene Is Associated with Familial Mandibular Prognathism.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/26124221","citation_count":36,"is_preprint":false},{"pmid":"22776012","id":"PMC_22776012","title":"Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis.","date":"2012","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/22776012","citation_count":36,"is_preprint":false},{"pmid":"27146815","id":"PMC_27146815","title":"Clinical significance of ADAMTS1, ADAMTS5, ADAMTS9 aggrecanases and IL-17A, IL-23, IL-33 cytokines in polycystic ovary syndrome.","date":"2016","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27146815","citation_count":35,"is_preprint":false},{"pmid":"2270435","id":"PMC_2270435","title":"Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblasts.","date":"1990","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2270435","citation_count":34,"is_preprint":false},{"pmid":"14760803","id":"PMC_14760803","title":"ADAMTS-1, a gene product of articular chondrocytes in vivo and in vitro, is downregulated by interleukin 1beta.","date":"2004","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/14760803","citation_count":34,"is_preprint":false},{"pmid":"20840749","id":"PMC_20840749","title":"PGF2α-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20840749","citation_count":33,"is_preprint":false},{"pmid":"27447109","id":"PMC_27447109","title":"The miR-181d-regulated metalloproteinase Adamts1 enzymatically impairs adipogenesis via ECM remodeling.","date":"2016","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/27447109","citation_count":32,"is_preprint":false},{"pmid":"15967414","id":"PMC_15967414","title":"Differential expression of genes coding for EGF-like factors and ADAMTS1 following gonadotropin stimulation in normal and transformed human granulosa cells.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15967414","citation_count":32,"is_preprint":false},{"pmid":"32408377","id":"PMC_32408377","title":"Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma.","date":"2020","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/32408377","citation_count":31,"is_preprint":false},{"pmid":"25998153","id":"PMC_25998153","title":"miR‑365 overexpression promotes cell proliferation and invasion by targeting ADAMTS-1 in breast cancer.","date":"2015","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25998153","citation_count":31,"is_preprint":false},{"pmid":"19007777","id":"PMC_19007777","title":"HDAC inhibition upregulates the expression of angiostatic ADAMTS1.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19007777","citation_count":30,"is_preprint":false},{"pmid":"11311987","id":"PMC_11311987","title":"A disintegrin and metalloprotease with thrombospondin type1 motifs (ADAMTS-1) and IL-1 receptor type 1 mRNAs are simultaneously induced in nerve injured motor neurons.","date":"2001","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11311987","citation_count":30,"is_preprint":false},{"pmid":"2571587","id":"PMC_2571587","title":"A human immunoglobulin IGHG3 allele (Gmb0,b1,c3,c5,u) with an IGHG4 converted region and three hinge exons.","date":"1989","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/2571587","citation_count":29,"is_preprint":false},{"pmid":"19027488","id":"PMC_19027488","title":"Aberrant methylation of ADAMTS1 in non-small cell lung cancer.","date":"2008","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19027488","citation_count":28,"is_preprint":false},{"pmid":"16900752","id":"PMC_16900752","title":"Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter.","date":"2006","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16900752","citation_count":28,"is_preprint":false},{"pmid":"19660812","id":"PMC_19660812","title":"Stringent regulation of complement lectin pathway C3/C5 convertase by C4b-binding protein (C4BP).","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19660812","citation_count":27,"is_preprint":false},{"pmid":"15777654","id":"PMC_15777654","title":"The hyalectan degrading ADAMTS-1 enzyme is expressed by osteoblasts and up-regulated at regions of new bone formation.","date":"2005","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15777654","citation_count":27,"is_preprint":false},{"pmid":"26563155","id":"PMC_26563155","title":"A disintegrin and metalloproteinase with thrombospondin motif 1 (ADAMTS1) expression increases in acute aortic dissection.","date":"2015","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26563155","citation_count":26,"is_preprint":false},{"pmid":"25142777","id":"PMC_25142777","title":"Adamts1 mediates ethanol-induced alterations in collagen and elastin via a FoxO1-sestrin3-AMPK signaling cascade in myocytes.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25142777","citation_count":25,"is_preprint":false},{"pmid":"19522863","id":"PMC_19522863","title":"ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer.","date":"2009","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/19522863","citation_count":25,"is_preprint":false},{"pmid":"35117030","id":"PMC_35117030","title":"ADAMTS-1 inhibits angiogenesis via the PI3K/Akt-eNOS-VEGF pathway in lung cancer cells.","date":"2019","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35117030","citation_count":24,"is_preprint":false},{"pmid":"23001403","id":"PMC_23001403","title":"Expression of ADAMTS1 and its correlation with angiogenesis in primary gastric cancer and lymph node metastasis.","date":"2012","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23001403","citation_count":23,"is_preprint":false},{"pmid":"20546609","id":"PMC_20546609","title":"ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20546609","citation_count":23,"is_preprint":false},{"pmid":"30166561","id":"PMC_30166561","title":"ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30166561","citation_count":22,"is_preprint":false},{"pmid":"24631293","id":"PMC_24631293","title":"ADAMTS1 inhibits lymphangiogenesis by attenuating phosphorylation of the lymphatic endothelial cell-specific VEGF receptor.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/24631293","citation_count":22,"is_preprint":false},{"pmid":"16303287","id":"PMC_16303287","title":"Differential expression of ADAMTS-1, -4, -5 and TIMP-3 in rat spinal cord at different stages of acute experimental autoimmune encephalomyelitis.","date":"2005","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/16303287","citation_count":22,"is_preprint":false},{"pmid":"23751571","id":"PMC_23751571","title":"Expression of ADAMTS1 mRNA in bovine endometrium and placenta during gestation.","date":"2013","source":"Domestic animal endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23751571","citation_count":21,"is_preprint":false},{"pmid":"23751874","id":"PMC_23751874","title":"Molecular characterization and transcriptional regulation of a disintegrin and metalloproteinase with thrombospondin motif 1 (ADAMTS1) in bovine preovulatory follicles.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23751874","citation_count":21,"is_preprint":false},{"pmid":"30402161","id":"PMC_30402161","title":"miR-365b-3p inhibits the cell proliferation and migration of human coronary artery smooth muscle cells by directly targeting ADAMTS1 in coronary atherosclerosis.","date":"2018","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30402161","citation_count":21,"is_preprint":false},{"pmid":"30446843","id":"PMC_30446843","title":"Abnormal expressions of ADAMTS-1, ADAMTS-9 and progesterone receptors are associated with lower oocyte maturation in women with polycystic ovary syndrome.","date":"2018","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/30446843","citation_count":21,"is_preprint":false},{"pmid":"31974739","id":"PMC_31974739","title":"ADAMTS1 and HSPG2 mRNA levels in cumulus cells are related to human oocyte quality and controlled ovarian hyperstimulation outcomes.","date":"2020","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31974739","citation_count":20,"is_preprint":false},{"pmid":"16949904","id":"PMC_16949904","title":"ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma.","date":"2006","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16949904","citation_count":20,"is_preprint":false},{"pmid":"22735305","id":"PMC_22735305","title":"Expression of ADAMTS-1, ADAMTS-4, ADAMTS-5 and TIMP3 by hepatocellular carcinoma cell lines.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22735305","citation_count":20,"is_preprint":false},{"pmid":"27844209","id":"PMC_27844209","title":"The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism.","date":"2016","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/27844209","citation_count":20,"is_preprint":false},{"pmid":"28570682","id":"PMC_28570682","title":"ADAMTS-1 in abdominal aortic aneurysm.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28570682","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52573,"output_tokens":8242,"usd":0.140675,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17995,"output_tokens":6060,"usd":0.120737,"stage2_stop_reason":"end_turn"},"total_usd":0.261412,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"ADAMTS1/METH-1 is a secreted, proteolytically processed protein with metalloprotease, disintegrin-like, and thrombospondin-type-1 repeat domains that inhibits endothelial cell proliferation and suppresses FGF-2- and VEGF-induced angiogenesis in vivo (cornea pocket and CAM assays), establishing it as an anti-angiogenic factor.\",\n      \"method\": \"Recombinant protein production, endothelial cell proliferation assay, cornea pocket assay, chorioallantoic membrane assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vivo and in vitro assays with recombinant protein, replicated across two model systems\",\n      \"pmids\": [\"10438512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ADAMTS1 is an active metalloprotease: it forms a covalent complex with alpha2-macroglobulin (proteinase trapping), and a point mutation in the zinc-binding motif abolishes this activity. The prodomain is removed by furin endopeptidase in the secretory pathway, as shown by impaired processing in furin-deficient LoVo cells restored by furin co-expression. The mature protein associates with the extracellular matrix.\",\n      \"method\": \"alpha2-macroglobulin trapping assay, zinc-binding domain point mutagenesis, furin-deficient cell line complementation, co-expression rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic activity confirmed by proteinase trapping, active-site mutagenesis, and genetic rescue in furin-deficient cells\",\n      \"pmids\": [\"10373500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Secreted pro-ADAMTS1 (METH-1) is processed in two consecutive steps: (1) furin cleaves the prodomain to release an 87 kDa active form (p87); (2) MMP-2, MMP-8, or MMP-15 further cleave p87 at the C-terminal end to release a 65 kDa form (p65) lacking two thrombospondin repeats. The p65 form shows reduced affinity for heparin and reduced suppression of endothelial cell proliferation compared to p87.\",\n      \"method\": \"Furin inhibitors, incubation with purified furin, MMP inhibitors, incubation with recombinant MMP-2/8/15, heparin affinity chromatography, endothelial cell proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — sequential processing demonstrated with purified enzymes, specific inhibitors, and functional readout\",\n      \"pmids\": [\"10944521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ADAMTS1 cleaves aggrecan at multiple sites including the Glu373-Ala site in the interglobular domain, classifying it as an aggrecanase. A point mutation in the zinc-binding domain abolishes catalytic activity; a furin-site mutant retains latency. ADAMTS1 is inhibited by TIMP-2 and TIMP-3 and by a specific monoclonal antibody.\",\n      \"method\": \"In vitro protease assay on ECM proteins, zinc-binding domain point mutagenesis, furin-site mutagenesis, peptide substrate activity assay, TIMP inhibition assay, monoclonal antibody neutralization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods including mutagenesis and inhibitor validation in a single study\",\n      \"pmids\": [\"12054629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ADAMTS1 inhibits VEGFR2 phosphorylation and endothelial cell proliferation by directly binding and sequestering VEGF165 via its C-terminal region. Binding requires the heparin-binding domain of VEGF165 (VEGF121, which lacks this domain, does not bind). The VEGF-ADAMTS1 complex is reversible, and active VEGF can be recovered. The complex was also detected in tumor extracts.\",\n      \"method\": \"Co-immunoprecipitation, chemical cross-linking, domain deletion analysis, VEGFR2 phosphorylation assay, endothelial cell proliferation assay, tumor extract co-IP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding confirmed by co-IP and cross-linking, domain mapping, functional VEGFR2 phosphorylation readout, and in vivo tumor extract validation\",\n      \"pmids\": [\"12716911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ADAMTS1 protein localizes to cytoplasmic secretory vesicles as a 110 kDa pro-form in mural granulosa cells, and accumulates as an 85 kDa mature form in the extracellular matrix of the cumulus-oocyte complex (COC) during matrix expansion. ADAMTS1 cleaves versican in the expanded COC matrix, generating a 70 kDa N-terminal fragment (neoepitope DPEAAE). Versican cleavage is reduced in PRKO mouse ovaries lacking ADAMTS1 induction.\",\n      \"method\": \"Peptide antibodies against pro-domain and metalloprotease domain, immunofluorescence, Western blot, neoepitope immunodetection, progesterone receptor knockout (PRKO) mouse model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — subcellular localization by immunofluorescence, substrate cleavage by neoepitope detection, genetic loss-of-function confirmation in PRKO mice\",\n      \"pmids\": [\"12907688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ADAMTS1 gene transcription in granulosa cells is co-regulated by LH (via cAMP/PKA/CEBP-beta) and progesterone receptor (PR-A/B acting as an inducible coregulator). Three Sp1/Sp3 GC-rich binding sites, a nuclear factor 1-like site, and CEBP-beta sites in the proximal promoter are required; PR stimulates promoter activity without a consensus PR response element.\",\n      \"method\": \"Promoter-luciferase reporter assays with truncations and site-specific mutants, transfection in rat granulosa cells, PR antagonist (ZK98299), PRA/PRB co-transfection, cAMP analogs\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple promoter deletion and mutagenesis constructs with pharmacological and genetic manipulation of the pathway\",\n      \"pmids\": [\"15256533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Fibulin-1 interacts with ADAMTS1 via the C-terminal region of ADAMTS1, as identified by yeast two-hybrid screening and confirmed by ligand affinity chromatography, co-immunoprecipitation, pulldown assays, and ELISA. Fibulin-1 acts as a cofactor, enhancing ADAMTS1-mediated cleavage of aggrecan without itself being a substrate.\",\n      \"method\": \"Yeast two-hybrid screen, ligand affinity chromatography, co-immunoprecipitation, pulldown assay, ELISA, in vitro aggrecan cleavage assay, in vivo co-localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding confirmed by four orthogonal methods, functional enhancement of protease activity demonstrated\",\n      \"pmids\": [\"16061471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ADAMTS1 is up-regulated in wounded skin; macrophages are the initial source, followed by keratinocytes and fibroblasts. At low concentrations, ADAMTS1 stimulates fibroblast migration via its proteolytic activity; at high concentrations it inhibits migration by binding FGF-2 and suppressing its pro-migratory activity. Similar dual effects are observed with endothelial cells.\",\n      \"method\": \"Immunofluorescence in wound tissue, ADAMTS1 knockout mouse skin phenotype, fibroblast/endothelial cell migration assays with recombinant ADAMTS1, protease-dead mutant, FGF-2 binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell-based assays with recombinant protein, protease-dead mutant, and KO mouse comparison, single lab\",\n      \"pmids\": [\"15843381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ADAMTS1 cleaves tissue factor pathway inhibitor-2 (TFPI-2), removing its protease-sensitive C-terminal region and altering its extracellular localization and binding properties. The interaction was identified by yeast two-hybrid screening and confirmed by biochemical and cell-based assays.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, biochemical cleavage assay, cell-based localization assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — yeast two-hybrid plus biochemical confirmation but single lab, limited functional follow-up\",\n      \"pmids\": [\"16641089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Proteomics (DIGE) identified nidogen-1, nidogen-2, desmocollin-3, dystroglycan-1, and Mac-2-binding protein as putative substrates of ADAMTS1 in conditioned medium; nidogen-1 and nidogen-2 were validated as cleavage substrates by immunochemical analysis.\",\n      \"method\": \"DIGE (2D difference gel electrophoresis), mass spectrometry, immunochemical validation, conditioned medium from ADAMTS1-overexpressing vs. parental cells\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — proteomics discovery with immunochemical validation, single lab, limited mechanistic depth\",\n      \"pmids\": [\"16511810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ADAMTS1 promotes tumor metastasis through its metalloproteinase activity: overexpression of full-length ADAMTS1 (but not a protease-dead mutant) promotes pulmonary metastasis and tumor angiogenesis, sheds membrane-bound HB-EGF and amphiregulin (AR), and activates EGFR and ErbB-2. Autoproteolytic N- and C-terminal fragments of ADAMTS1 each inhibit metastasis and suppress Erk1/2 activation by soluble HB-EGF and AR.\",\n      \"method\": \"Overexpression of full-length vs. protease-dead ADAMTS1 mutant (E/Q) and cleavage fragments in tumor cell lines, pulmonary metastasis assay in mice, EGFR/ErbB-2 phosphorylation assay, EGF ligand shedding assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytic mutant vs. WT comparison, multiple cell lines, in vivo metastasis model, mechanistic signaling readouts\",\n      \"pmids\": [\"16314835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Endocardial Brg1 (a chromatin remodeling protein) represses ADAMTS1 expression in the endocardium overlying developing trabeculae. ADAMTS1, a secreted matrix metalloproteinase, degrades cardiac jelly components; its repression is required for trabecular growth. Later in embryogenesis, ADAMTS1 expression initiates in the endocardium to degrade cardiac jelly and limit excessive trabeculation.\",\n      \"method\": \"Genetic mouse models (Brg1 conditional knockout in endocardium), in vivo cardiac phenotyping, expression analysis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO genetic epistasis with defined morphogenetic phenotype, two developmental timepoints studied\",\n      \"pmids\": [\"18267097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ADAMTS1 cleaves the ectodomain of syndecan-4, resulting in altered cytoskeletal organization, loss of focal adhesions, and increased cell migration. ADAMTS1 proteolytic action phenocopies genetic deletion of syndecan-4 with respect to focal adhesions.\",\n      \"method\": \"Recombinant ADAMTS1 cleavage of syndecan-4, syndecan-4 null cells, immunofluorescence of cytoskeletal components, focal adhesion assay, migration assay\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — substrate cleavage demonstrated, phenotype validated with genetic null cells, multiple orthogonal readouts\",\n      \"pmids\": [\"18775505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADAMTS1 and MMP1 orchestrate a paracrine signaling cascade in bone metastasis: they proteolytically release membrane-bound EGF-like growth factors (AREG, HB-EGF, TGFα) from tumor cells, which suppress OPG expression in osteoblasts and potentiate osteoclast differentiation, promoting osteolytic bone metastasis. EGFR inhibitors block this cascade in bone stromal cells.\",\n      \"method\": \"Gain-of-function in tumor cell lines, conditioned medium transfer to osteoblasts, EGFR inhibitor treatment, osteoclast differentiation assay, bone metastasis mouse model\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-step paracrine pathway validated in vitro and in vivo with mechanistic inhibitor experiments\",\n      \"pmids\": [\"19608765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADAMTS1 cleaves semaphorin 3C, releasing it from the extracellular matrix, and this cleavage promotes migration of breast cancer cells. Identified by two complementary proteomics approaches (DIGE and SILAC).\",\n      \"method\": \"DIGE and SILAC proteomics, recombinant ADAMTS1 overexpression, mass spectrometry substrate identification, breast cancer cell migration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — two orthogonal proteomics approaches, functional migration readout, single lab\",\n      \"pmids\": [\"19915008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Hypoxia transiently induces ADAMTS1 mRNA and protein specifically in endothelial cells (not other cell types) via HIF-1 binding to at least three HIF binding sites in the ADAMTS1 promoter, as confirmed by chromatin immunoprecipitation. This induction is blocked by PI3K inhibitor LY294002. Recombinant ADAMTS1 promotes HUVEC migration under hypoxic conditions.\",\n      \"method\": \"Hypoxia and CoCl2 treatment, real-time PCR, Western blot, promoter-luciferase assay, chromatin immunoprecipitation (ChIP), PI3K inhibitor, cell migration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms HIF-1 binding, PI3K-dependence shown pharmacologically, functional migration readout; single lab with multiple methods\",\n      \"pmids\": [\"19349275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ADAMTS1 cleaves thrombospondin-1 (TSP1), and this cleavage is organ-context-dependent: cleavage occurs more efficiently in liver than lung lysates, and ADAMTS1 inhibition (neutralizing antibody, siRNA, or genetic deletion) abrogates TSP1 cleavage. Differential ADAMTS1-mediated TSP1 processing underlies the variable anti-metastatic efficacy of TSP1 in liver vs. lung. [Note: this paper was retracted.]\",\n      \"method\": \"TSP1 cleavage assay in liver vs. lung lysates, neutralizing antibody, siRNA knockdown, Adamts1 knockout mice, metastasis models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2 / Weak — paper was subsequently retracted; findings cannot be relied upon\",\n      \"pmids\": [\"20103648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ADAMTS1 is required for mammary tumor growth and metastasis in vivo: Adamts1 knockout in the MMTV-PyMT mouse model significantly reduces tumor burden and lung metastasis, with increased apoptosis and increased cytotoxic immune cell activation. Adamts1-null tumor stroma shows less proteolytically cleaved versican and increased CD45+ leukocyte infiltration.\",\n      \"method\": \"Adamts1 knockout mouse crossed with MMTV-PyMT mammary tumor model, histology, apoptosis assay, versican neoepitope immunostaining, immune cell phenotyping (IL-12, CD45)\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined in vivo phenotypic readouts, substrate cleavage, and immune cell characterization\",\n      \"pmids\": [\"22001177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In kidney pericytes, ADAMTS1 expression is rapidly activated after injury and contributes to microvascular destabilization, while TIMP3 (its inhibitor) stabilizes capillary tube networks. TIMP3-null mice show spontaneous microvascular phenotype with overactivated pericytes and increased susceptibility to injury-stimulated microvascular rarefaction.\",\n      \"method\": \"Gene expression profiling in kidney pericytes in vivo, 3D capillary tube assay, Timp3 knockout mouse, pericyte differentiation experiments\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gene activation, functional 3D tube assay, and genetic KO validation\",\n      \"pmids\": [\"22383695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAMTS1 acts as a tumor suppressor in breast cancer xenografts by cleaving nidogen-1 and nidogen-2 from vascular basement membranes, disrupting vessel morphology and reducing vessel density. Increased ADAMTS1 expression causes near-complete inhibition of tumor growth and correlates with nidogen cleavage.\",\n      \"method\": \"Xenograft tumor model, ADAMTS1 overexpression, immunostaining for nidogens and vessels, microvessel density quantification\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo xenograft with functional substrate (nidogen) cleavage readout, single lab\",\n      \"pmids\": [\"23681936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADAMTS1 inhibits lymphangiogenesis by forming a complex with VEGF-C and attenuating phosphorylation of VEGFR3 in lymphatic endothelial cells. Immunoprecipitation assays confirmed ADAMTS1-VEGF-C complex formation.\",\n      \"method\": \"Adenoviral ADAMTS1 gene transduction of lymphatic endothelial cells, cell proliferation assay, tube formation assay, migration assay, VEGFR3 phosphorylation assay, co-immunoprecipitation\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP confirms complex, functional VEGFR3 phosphorylation readout, single lab\",\n      \"pmids\": [\"24631293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ADAMTS1 is required for SPARC-induced collagen deposition in aging myocardium. SPARC stimulation of cardiac fibroblasts increases secretion of both latent (110 kDa) and active (87 kDa) ADAMTS1 forms and promotes collagen I secretion; an ADAMTS1 blocking antibody suppresses SPARC-induced collagen I secretion. ADAMTS1 substrate versican decreases with age only in wild-type mice (not SPARC-null), linking SPARC-ADAMTS1 to proteoglycan turnover.\",\n      \"method\": \"SPARC-null mice, cardiac fibroblast stimulation with SPARC, ADAMTS1 blocking antibody, Western blot, picrosirius red staining, versican immunostaining\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — blocking antibody functional validation and SPARC-null mouse genetic evidence, single lab\",\n      \"pmids\": [\"27143554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Adamts1 metalloprotease activity impairs adipocyte commitment by remodeling ECM components and activating FAK-ERK signaling. miR-181d targets and represses Adamts1 to permit adipocytic lineage commitment. Ablation of Adamts1 in adipose tissue increases adipose mass and disrupts lipid homeostasis. The catalytic activity of Adamts1 is required for this inhibitory effect.\",\n      \"method\": \"Forced expression and siRNA knockdown of Adamts1, catalytic domain mutagenesis, adipogenesis differentiation assay, FAK-ERK signaling analysis, adipose-specific Adamts1 knockout mice, miR-181d target validation\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytic mutant distinguishes protease-dependent mechanism, KO mice, multiple signaling readouts, miRNA-target validation\",\n      \"pmids\": [\"27447109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Macrophage-derived ADAMTS1 promotes satellite cell (muscle stem cell) activation by cleaving NOTCH1, thereby reducing Notch signaling. Overexpression of Adamts1 in macrophages in vivo is sufficient to increase satellite cell activation and improve muscle regeneration. NOTCH1 is identified as a direct substrate of ADAMTS1 metalloproteinase activity.\",\n      \"method\": \"Macrophage-specific Adamts1 overexpression in vivo, satellite cell activation assay, Notch signaling analysis, NOTCH1 substrate cleavage assay, muscle injury model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — substrate identified, in vivo overexpression with defined cellular phenotype, Notch signaling mechanistic readout\",\n      \"pmids\": [\"28939843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Genetic haploinsufficiency of Adamts1 in mice causes thoracic aortic aneurysm and dissection (TAAD) associated with elevated aortic nitric oxide and Nos2 levels. Nos2 inactivation or pharmacological NOS2 inhibition protects Adamts1-deficient mice from aortic pathology and rapidly reverses aortic dilation and medial degeneration, placing ADAMTS1 upstream of the NOS2 axis in vascular homeostasis.\",\n      \"method\": \"Adamts1 haploinsufficient mice, Nos2 genetic knockout, NOS2 pharmacological inhibition, aortic histology and diameter measurement, nitric oxide quantification\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double mutant), pharmacological rescue, mechanistic pathway placement\",\n      \"pmids\": [\"28067899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADAMTS1 and syndecan-4 are functionally interconnected in regulating endothelial cell adhesion, migration, and angiogenesis. Knockdown of ADAMTS1 in endothelial cells reduces cell-surface syndecan-4 levels via increased MMP9 activity. Both ADAMTS1 and syndecan-4 knockdowns enhance VEGFA164 responses and aortic ring sprouting. Fibulin-1, an ADAMTS1 co-factor, is absent from conditioned matrix of knockdown cells and correlates with altered migration.\",\n      \"method\": \"siRNA knockdown of ADAMTS1 and syndecan-4, MMP9 activity assay, VEGFA response assay, ex vivo aortic ring sprouting, conditioned matrix experiment, fibulin-1 expression analysis\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA knockdowns with parallel functional readouts, matrix-dependent phenotype confirmed, single lab\",\n      \"pmids\": [\"32269093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ADAMTS1 cleaves versican V1 at the canonical Glu441-Ala442 site and at multiple additional sites (21 novel sites with a P1-Glu preference), as determined by label-free quantitative LC-MS/MS proteomics comparing active vs. catalytically inactive ADAMTS1 digests of purified versican V1.\",\n      \"method\": \"In vitro digestion of recombinant versican V1 with recombinant ADAMTS1 vs. catalytically inactive mutant, LC-MS/MS, semi-tryptic peptide z-score analysis\",\n      \"journal\": \"Journal of proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins, catalytically inactive control, mass spectrometry site mapping\",\n      \"pmids\": [\"34450332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"VEGF upregulates ADAMTS1 expression in endothelial cells via VEGFR2 → phospholipase C-gamma → PKCbeta signaling. Knockdown of endogenous ADAMTS1 by siRNA increases endothelial cell proliferation, indicating ADAMTS1 is an endogenous brake on endothelial proliferation downstream of VEGF.\",\n      \"method\": \"VEGF stimulation, VEGFR2 and PLC-gamma inhibitors, PKC inhibitors (calphostin C, PKCbeta-specific inhibitor), siRNA knockdown, [3H]-thymidine incorporation proliferation assay\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological pathway dissection with multiple specific inhibitors, siRNA loss-of-function, functional proliferation readout\",\n      \"pmids\": [\"16936124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HDAC6 and SP1 repress ADAMTS1 transcription via proximal GC-box elements. HDAC inhibitors (TSA, SAHA) and HDAC6-specific inhibitor tubacin upregulate ADAMTS1 expression. ChIP and DAPA assays confirm decreased SP1 and HDAC6 binding to the ADAMTS1 promoter after TSA treatment.\",\n      \"method\": \"Promoter-luciferase reporter assay, ChIP (chromatin immunoprecipitation), DAPA (DNA affinity precipitation assay), HDAC inhibitors, HDAC6 knockdown, SP1 analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and DAPA confirm direct binding, pharmacological and siRNA evidence, single lab\",\n      \"pmids\": [\"19007777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ethanol increases O-GlcNAc modification of Adamts1 and decreases its interaction with endogenous inhibitor TIMP3 in myocytes, leading to increased collagen I and decreased elastin. Silencing Adamts1 by siRNA blocks ethanol-induced collagen/elastin changes. This is controlled upstream by FoxO1-sestrin3-AMPK signaling.\",\n      \"method\": \"siRNA knockdown of Adamts1, MMP pharmacological inhibition, O-GlcNAc modification detection, TIMP3 co-immunoprecipitation, FoxO1/AMPK pathway inhibitors, collagen/elastin quantification in C2C12 myocytes\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA and pharmacological inhibition with pathway dissection, single lab, single cell type\",\n      \"pmids\": [\"25142777\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADAMTS1 is a secreted zinc metalloprotease activated by furin-mediated prodomain removal (and further processed by MMPs) that cleaves extracellular matrix substrates including aggrecan, versican, nidogen-1/2, syndecan-4, semaphorin 3C, TFPI-2, and NOTCH1; sequesters VEGF165 and VEGF-C via its C-terminal thrombospondin repeats to suppress VEGFR2 and VEGFR3 phosphorylation; is regulated transcriptionally by HIF-1, LH/PR, VEGF-PKCβ, and HDAC6/SP1; functions in vascular homeostasis through an ADAMTS1-NOS2 axis; and plays context-dependent roles in ovulation, myocardial trabeculation, muscle stem cell activation via Notch cleavage, adipogenesis, and tumor progression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADAMTS1 (METH-1) is a secreted, extracellular-matrix-associated zinc metalloprotease that remodels the pericellular matrix and modulates angiogenic and morphogenetic signaling, establishing it as an anti-angiogenic and matrix-remodeling factor [#0, #1]. It is produced as a latent proenzyme that is activated by furin-mediated prodomain removal in the secretory pathway, then further processed by MMP-2/8/15 at its C-terminus to generate a p65 form that loses two thrombospondin repeats, reduced heparin affinity, and reduced anti-proliferative activity [#1, #2]; catalysis depends on an intact zinc-binding motif and is restrained by TIMP-2 and TIMP-3 [#3]. Through its proteolytic activity ADAMTS1 cleaves an extensive set of matrix and cell-surface substrates including aggrecan, versican (generating the DPEAAE neoepitope), nidogen-1/2, syndecan-4, semaphorin 3C, TFPI-2, and NOTCH1, and sheds membrane-bound EGF-family ligands (HB-EGF, amphiregulin, TGFα) [#3, #5, #10, #13, #15, #24, #11, #27]; fibulin-1 acts as a cofactor that enhances aggrecan cleavage [#7]. Independent of catalysis, ADAMTS1 sequesters the heparin-binding forms of VEGF165 and VEGF-C via its C-terminal thrombospondin repeats to suppress VEGFR2 and VEGFR3 phosphorylation and endothelial/lymphatic proliferation [#4, #21]. Its expression is tightly controlled: induced by LH/cAMP/PKA and progesterone receptor in ovulating granulosa cells [#6], by hypoxia through HIF-1 in endothelial cells [#16], and downstream of VEGF–VEGFR2–PLCγ–PKCβ signaling [#28], and repressed by HDAC6/SP1 [#29]. These activities translate into context-dependent physiological roles in ovulation through versican cleavage [#5], cardiac trabeculation through cardiac jelly degradation [#12], muscle stem cell activation through NOTCH1 cleavage [#24], adipocyte commitment via FAK-ERK signaling [#23], vascular homeostasis through an ADAMTS1–NOS2 axis whose disruption causes thoracic aortic aneurysm [#25], and both pro- and anti-tumorigenic effects in breast, bone, and pulmonary metastasis [#11, #14, #18, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing that the protein is a genuine secreted enzyme and an anti-angiogenic factor defined the foundational identity of ADAMTS1.\",\n      \"evidence\": \"Recombinant protein in endothelial proliferation, cornea pocket, and CAM assays; alpha2-macroglobulin trapping, zinc-motif mutagenesis, and furin-deficient cell complementation\",\n      \"pmids\": [\"10438512\", \"10373500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological substrate(s) not yet identified\", \"Mechanism of anti-angiogenesis (proteolytic vs. binding) not resolved at this stage\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defining sequential furin then MMP processing showed activation and maturation generate functionally distinct forms, explaining how proteolytic state tunes activity.\",\n      \"evidence\": \"Furin/MMP inhibitors and purified enzymes, heparin affinity chromatography, endothelial proliferation readout\",\n      \"pmids\": [\"10944521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger for C-terminal processing in vivo unclear\", \"Functional role of the released C-terminal TSR fragments not defined here\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying ADAMTS1 as an aggrecanase with defined inhibitor sensitivity placed it in matrix proteoglycan turnover.\",\n      \"evidence\": \"In vitro ECM protease assays, zinc-motif and furin-site mutants, TIMP-2/3 and monoclonal antibody inhibition\",\n      \"pmids\": [\"12054629\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of aggrecan cleavage in tissue not established\", \"Substrate repertoire beyond aggrecan not yet mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery of direct VEGF165 sequestration via the C-terminal region revealed a catalysis-independent mechanism for anti-angiogenesis.\",\n      \"evidence\": \"Co-IP, cross-linking, domain deletion, VEGFR2 phosphorylation assay, tumor extract validation\",\n      \"pmids\": [\"12716911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of sequestration vs. proteolysis to angiogenesis in vivo unclear\", \"Reversibility implications for tissue VEGF bioavailability untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating ovary-specific versican cleavage and subcellular trafficking linked ADAMTS1 proteolysis to a defined physiological process, ovulation.\",\n      \"evidence\": \"Domain-specific antibodies, immunofluorescence, versican neoepitope detection, PRKO mouse\",\n      \"pmids\": [\"12907688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether versican cleavage alone is sufficient for COC expansion not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapping the LH/cAMP/PKA and PR-coregulated promoter explained how ADAMTS1 is transcriptionally induced during ovulation.\",\n      \"evidence\": \"Promoter-luciferase truncation/mutant constructs, PR antagonist, PRA/PRB co-transfection, cAMP analogs in granulosa cells\",\n      \"pmids\": [\"15256533\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PR acts without a consensus PRE not mechanistically resolved\", \"Generality of this regulation outside granulosa cells unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying fibulin-1 as a binding cofactor that enhances aggrecan cleavage showed ADAMTS1 activity is modulated by ECM partners.\",\n      \"evidence\": \"Yeast two-hybrid, affinity chromatography, co-IP, pulldown, ELISA, in vitro aggrecan cleavage\",\n      \"pmids\": [\"16061471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of fibulin-1-mediated enhancement unknown\", \"Whether fibulin-1 modulates other substrates not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating concentration-dependent dual control of cell migration (proteolytic stimulation vs. FGF-2 sequestration) revealed ADAMTS1 as a context-dependent migration regulator in wound healing.\",\n      \"evidence\": \"Wound-tissue immunofluorescence, KO mouse skin, migration assays with recombinant/protease-dead protein, FGF-2 binding\",\n      \"pmids\": [\"15843381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Local concentration thresholds in tissue not defined\", \"FGF-2 sequestration domain not precisely mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Expanding the substrate set (TFPI-2, nidogen-1/2 and other proteomics hits) and defining VEGF-driven induction broadened both the enzymatic repertoire and upstream regulation of ADAMTS1.\",\n      \"evidence\": \"Yeast two-hybrid plus biochemical cleavage; DIGE/MS with immunochemical validation; VEGF stimulation with VEGFR2/PLCγ/PKC inhibitors and siRNA\",\n      \"pmids\": [\"16641089\", \"16511810\", \"16936124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of TFPI-2 and nidogen cleavage in tissue not established\", \"Several DIGE-identified substrates remain unvalidated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying syndecan-4 cleavage, HDAC6/SP1 repression, and Brg1-controlled cardiac repression connected ADAMTS1 to cytoskeletal/adhesion control, epigenetic regulation, and heart morphogenesis.\",\n      \"evidence\": \"Recombinant cleavage with syndecan-4 null cells and focal adhesion/migration assays; promoter-luciferase, ChIP, DAPA with HDAC inhibitors; Brg1 conditional endocardial KO with cardiac phenotyping\",\n      \"pmids\": [\"18775505\", \"19007777\", \"18267097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single protease coordinates these distinct outputs in vivo unclear\", \"HDAC6/SP1 repression evidence from a single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linking ADAMTS1 to EGF-ligand shedding, semaphorin 3C cleavage, paracrine bone metastasis, and HIF-1 hypoxic induction defined its proteolytic role in tumor signaling and stress-responsive expression.\",\n      \"evidence\": \"WT vs. protease-dead overexpression and metastasis models; DIGE/SILAC proteomics with migration assays; conditioned-medium transfer to osteoblasts with EGFR inhibitors; hypoxia/ChIP with HIF-1 binding sites\",\n      \"pmids\": [\"16314835\", \"19915008\", \"19608765\", \"19349275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciling pro- vs. anti-tumor roles across contexts not resolved\", \"Semaphorin 3C cleavage from a single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic loss in a mammary tumor model showed ADAMTS1 is required for tumor growth and metastasis and shapes the immune/versican tumor microenvironment.\",\n      \"evidence\": \"Adamts1 KO crossed with MMTV-PyMT, histology, apoptosis, versican neoepitope, CD45/IL-12 immune phenotyping\",\n      \"pmids\": [\"22001177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether immune effects are downstream of versican cleavage not directly tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Implicating ADAMTS1 in pericyte-driven microvascular destabilization opposed by TIMP3 extended its vascular role to injury-induced rarefaction.\",\n      \"evidence\": \"In vivo pericyte expression profiling, 3D capillary tube assay, Timp3 KO mouse\",\n      \"pmids\": [\"22383695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate mediating destabilization not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing VEGF-C sequestration that suppresses VEGFR3 generalized the C-terminal ligand-trapping mechanism to lymphangiogenesis.\",\n      \"evidence\": \"Adenoviral ADAMTS1 in lymphatic endothelial cells, proliferation/tube/migration assays, VEGFR3 phosphorylation, co-IP\",\n      \"pmids\": [\"24631293\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP; in vivo relevance to lymphatic biology untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defining nidogen cleavage that disrupts vascular basement membranes assigned ADAMTS1 a tumor-suppressive anti-angiogenic mechanism in breast xenografts.\",\n      \"evidence\": \"Xenograft with ADAMTS1 overexpression, nidogen and vessel immunostaining, microvessel density\",\n      \"pmids\": [\"23681936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; contrasts with pro-metastatic roles in other models\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Distinguishing protease-dependent control of adipocyte commitment and SPARC-driven cardiac collagen deposition refined ADAMTS1's roles in lineage commitment and cardiac matrix remodeling.\",\n      \"evidence\": \"Catalytic mutant, adipose-specific KO, FAK-ERK readouts, miR-181d targeting; SPARC-null mice, fibroblast stimulation, blocking antibody, versican immunostaining\",\n      \"pmids\": [\"27447109\", \"27143554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ECM substrate driving adipocyte FAK-ERK signaling not pinpointed\", \"SPARC-ADAMTS1 collagen link from a single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying NOTCH1 as a direct substrate for muscle stem cell activation and placing ADAMTS1 upstream of the NOS2 vascular axis (aortic aneurysm) demonstrated specific in vivo signaling and disease mechanisms.\",\n      \"evidence\": \"Macrophage-specific Adamts1 overexpression with NOTCH1 cleavage/satellite cell assays; Adamts1 haploinsufficient mice with Nos2 KO and pharmacological NOS2 inhibition\",\n      \"pmids\": [\"28939843\", \"28067899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NOS2 is regulated downstream of ADAMTS1 not molecularly defined\", \"Substrate connecting ADAMTS1 loss to NOS2 elevation unidentified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connecting ADAMTS1, syndecan-4, MMP9, and fibulin-1 in endothelial adhesion and VEGFA responses integrated several earlier partners into one angiogenic regulatory network.\",\n      \"evidence\": \"siRNA knockdowns, MMP9 activity, VEGFA response, aortic ring sprouting, conditioned matrix and fibulin-1 analysis\",\n      \"pmids\": [\"32269093\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causality among the network nodes incompletely resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"High-resolution mapping of versican V1 cleavage sites with a catalytically inactive control provided definitive enzymatic characterization of a principal substrate.\",\n      \"evidence\": \"In vitro digestion of recombinant versican V1, active vs. inactive ADAMTS1, label-free LC-MS/MS\",\n      \"pmids\": [\"34450332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biological role of the 21 novel cleavage sites in tissue not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ADAMTS1's many context-dependent roles (pro- vs. anti-angiogenic, pro- vs. anti-tumor) are selected by tissue, processing state, cofactor availability, and substrate context remains the central unresolved question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying framework reconciling opposing phenotypes\", \"Relative in vivo contributions of catalytic vs. ligand-sequestering activities unquantified\", \"Structural basis of substrate and cofactor selectivity unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 5, 10, 13, 15, 24, 27]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 2, 3]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [4, 21, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [1, 5, 20]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [3, 5, 13, 20, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 11, 14, 24, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 14, 18, 25]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FBLN1\", \"VEGFA\", \"VEGFC\", \"TIMP3\", \"TIMP2\", \"SDC4\", \"A2M\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}